Test drug APG-157 for abnormal mouth tissue
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 2 trial studies whether APG-157 can safely improve abnormal cells in the mouth (dysplasia) or early cancer-like changes (carcinoma in situ). You may be eligible if you have a visible, biopsy-proven lesion and can take oral medication while meeting blood and health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (over 18) with a visible abnormal mouth or throat lesion and a biopsy showing moderate-to-severe dysplasia or carcinoma in situ
- Have a lesion big enough to measure (at least 8 mm by 3 mm before the biopsy)
- Be willing to provide blood samples, an oral rinse, and tissue from required diagnostic biopsies
- Have blood-test results that are high enough for safety (white blood cells, neutrophils, and platelets) and liver tests within allowed limits
- Not be pregnant and agree to use effective birth control during the study (or be post-menopausal or have a vasectomy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called APG-157 for people with advanced head and neck cancer that hasn't spread. It may be given before or instead of surgery, and the goal is to see if it helps shrink tumors or control the disease.
This study tests an experimental medication called CAN1012 for people with oral dysplasia, a pre-cancerous condition in the mouth. The goal is to see if it is safe and can help prevent the condition from becoming cancer.
This study tests two experimental drugs for people with neuroblastoma or other solid tumors that have not responded to standard treatment. APG-115 is given alone or with APG-2575 to see if it can shrink tumors and help patients feel better.
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
This trial tests a combination of two drugs given before surgery for advanced mouth or throat cancer. The drugs may help shrink tumors and improve the chance of successful surgery. It is specifically for patients whose cancer has high levels of PD-L1 and EGFR proteins.
This trial tests whether PRV111, PRV211, and PRV131 are safe and work better than expected for certain mouth (lip/oral cavity) cancers and lung cancers. It may help by trying a new approach given directly to the tumor and then monitoring how well it shrinks and how safe it is.
Hear when a new Oropharyngeal Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.